Selecta Biosciences - SELB Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $2.80
  • Forecasted Upside:
  • Number of Analysts: 6
  • Breakdown:
  • 0 Sell Ratings
  • 3 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$0.00
+0 (0.00%)
Get New Selecta Biosciences Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SELB and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SELB

Analyst Price Target is $2.80
▲ +∞ Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Selecta Biosciences in the last 3 months. The average price target is $2.80, with a high forecast of $5.00 and a low forecast of $1.00. The average price target represents a ∞ upside from the last price of $0.00.

This chart shows the closing price for SELB for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 6 polled investment analysts is to moderate buy stock in Selecta Biosciences. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 3 hold ratings
  • 0 sell ratings
12/3/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 3 hold ratings
  • 0 sell ratings
3/3/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 3 hold ratings
  • 0 sell ratings
6/1/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 3 hold ratings
  • 0 sell ratings
8/30/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 3 hold ratings
  • 0 sell ratings
11/28/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 3 hold ratings
  • 0 sell ratings
2/26/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 3 hold ratings
  • 0 sell ratings
4/26/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 3 hold ratings
  • 0 sell ratings
5/26/2024

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 3 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/18/2023Leerink PartnrsDowngradeOutperform ➝ Market PerformLow
8/18/2023Needham & Company LLCLower TargetBuy ➝ Buy$5.00 ➝ $4.00Low
8/18/2023HC WainwrightReiterated RatingBuy ➝ Buy$5.00Low
8/18/2023SVB LeerinkReiterated RatingOutperform ➝ Market Perform$1.00Low
8/18/2023MizuhoLower TargetBuy ➝ Buy$4.00 ➝ $3.00Low
8/18/2023SVB SecuritiesDowngradeOutperform ➝ Market Perform$1.00Low
4/13/2023Needham & Company LLCReiterated RatingBuy$5.00Low
3/22/2023HC WainwrightBoost TargetBuy$4.00 ➝ $5.00Low
3/22/2023MizuhoLower TargetBuy$5.00 ➝ $4.00Low
3/21/2023Needham & Company LLCReiterated RatingBuy$5.00Low
3/3/2023Needham & Company LLCReiterated RatingBuy$5.00Low
3/3/2023MizuhoLower Target$8.00 ➝ $5.00Low
1/31/2023Canaccord Genuity GroupLower TargetBuy$10.00 ➝ $9.00Low
6/21/2022HC WainwrightLower TargetBuy$6.00 ➝ $4.00Low
6/14/2022Needham & Company LLCLower TargetBuy$6.00 ➝ $5.00High
6/6/2022SVB LeerinkInitiated CoverageOutperform$7.00High
1/11/2022HC WainwrightReiterated RatingBuy$6.00Low
12/2/2021HC WainwrightReiterated RatingBuy$6.00High
11/15/2021HC WainwrightReiterated RatingBuy$6.00Low
11/1/2021Needham & Company LLCBoost TargetBuy$6.00 ➝ $7.00Medium
10/22/2021HC WainwrightReiterated RatingBuy$6.00Low
10/11/2021Needham & Company LLCReiterated RatingBuy$6.00Low
10/5/2021HC WainwrightReiterated RatingBuy$6.00High
9/9/2021HC WainwrightReiterated RatingBuy$6.00Low
9/2/2021HC WainwrightReiterated RatingBuy$6.00High
7/27/2021Berenberg BankReiterated RatingBuy$3.50Medium
7/27/2021HC WainwrightReiterated RatingBuy$6.00Medium
6/14/2021BTIG ResearchInitiated CoverageBuy$10.00High
5/3/2021HC WainwrightReiterated RatingBuyLow
3/12/2021William BlairUpgradeMarket Perform ➝ OutperformHigh
1/26/2021MizuhoUpgradeNeutral ➝ Buy$2.50 ➝ $8.00High
1/7/2021HC WainwrightReiterated RatingBuy$6.00N/A
10/9/2020Cantor FitzgeraldReiterated RatingOverweightLow
10/5/2020HC WainwrightLower TargetBuy$10.00 ➝ $6.00Low
10/1/2020MizuhoDowngradeBuy ➝ Neutral$7.00 ➝ $2.50High
10/1/2020William BlairDowngradeOutperform ➝ Market PerformHigh
8/7/2020MizuhoReiterated RatingBuy$7.00Medium
6/18/2020HC WainwrightReiterated RatingBuy$10.00High
6/18/2020Stifel NicolausReiterated RatingHoldHigh
6/18/2020Needham & Company LLCReiterated RatingBuy$5.00Medium
6/12/2020Needham & Company LLCReiterated RatingBuy$5.00High
6/12/2020Stifel NicolausDowngradeBuy ➝ Hold$4.00High
6/12/2020HC WainwrightBoost TargetBuy$8.00 ➝ $10.00High
6/10/2020MizuhoReiterated RatingBuy$7.00Low
5/7/2020Stifel NicolausReiterated RatingBuy$4.00High
5/7/2020Needham & Company LLCReiterated RatingBuy$5.00High
5/7/2020William BlairReiterated RatingBuyHigh
4/28/2020HC WainwrightInitiated CoverageBuy$8.00High
3/12/2020Stifel NicolausReiterated RatingBuy$4.00High
2/18/2020MizuhoReiterated RatingBuy$4.00 ➝ $7.00High
1/29/2020Cantor FitzgeraldInitiated CoverageOverweight$10.00Low
1/21/2020William BlairInitiated CoverageOutperformHigh
12/19/2019MizuhoReiterated RatingBuy$4.00Low
12/19/2019Stifel NicolausReiterated RatingBuyHigh
11/8/2019Needham & Company LLCReiterated RatingBuy$9.00Low
11/8/2019Stifel NicolausReiterated RatingBuy$6.00Low
8/11/2019MizuhoReiterated RatingBuy$4.00Medium
8/9/2019Stifel NicolausReiterated RatingBuy$6.00Low
(Data available from 5/27/2019 forward)

News Sentiment Rating

0.00 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/30/2023
  • 2 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
11/29/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/29/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/28/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/27/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/28/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/27/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/27/2024

Current Sentiment

  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Selecta Biosciences logo
Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's lead therapeutic gene therapy program is SEL-302 that is in Phase I clinical trial to enhance the treatment of methylmalonic acidemia. It is also developing biologic therapies, such as SEL-212 that is in Phase III clinical trials for the treatment of chronic refractory gout; and product candidates to treat IgA-mediated diseases, including IgA nephropathy, linear IgA bullous dermatitis, IgA pemphigus, and Henoch-Schonlein purpura. In addition, the company is developing gene therapies comprising for the treatment of pompe disease, duchenne muscular dystrophy, limb-girdle muscular dystrophy, lysosomal storage disorder, and other autoimmune diseases. Further, it develops tolerogenic therapies to treat autoimmune diseases. The company has license and collaboration agreements with Ginkgo Bioworks Holdings, Inc.; Genovis AB (publ.); Cyrus Biotechnology, Inc.; IGAN Biosciences, Inc.; Astellas Therapeutics, Inc.; Takeda Pharmaceuticals USA, Inc.; Swedish Orphan Biovitrum AB (publ.); Sarepta Therapeutics, Inc.; Asklepios Biopharmaceutical, Inc.; Massachusetts Institute of Technology; and Shenyang Sunshine Pharmaceutical Co., Ltd. Selecta Biosciences, Inc. was incorporated in 2007 and is headquartered in Watertown, Massachusetts.
Read More

Today's Range

Now: N/A

50 Day Range

MA: $1.06
Low: $0.88
High: $1.26

52 Week Range

Now: N/A

Volume

2,774,100 shs

Average Volume

979,585 shs

Market Capitalization

$136.76 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.84

Frequently Asked Questions

What sell-side analysts currently cover shares of Selecta Biosciences?

The following Wall Street analysts have issued reports on Selecta Biosciences in the last year: HC Wainwright, Leerink Partnrs, Mizuho, Needham & Company LLC, StockNews.com, SVB Leerink LLC, and SVB Securities.
View the latest analyst ratings for SELB.

What is the current price target for Selecta Biosciences?

5 Wall Street analysts have set twelve-month price targets for Selecta Biosciences in the last year. Their average twelve-month price target is $2.80. HC Wainwright has the highest price target set, predicting SELB will reach $5.00 in the next twelve months. SVB Leerink LLC has the lowest price target set, forecasting a price of $1.00 for Selecta Biosciences in the next year.
View the latest price targets for SELB.

What is the current consensus analyst rating for Selecta Biosciences?

Selecta Biosciences currently has 3 hold ratings and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for SELB.

What other companies compete with Selecta Biosciences?

How do I contact Selecta Biosciences' investor relations team?

Selecta Biosciences' physical mailing address is 65 Grove Street, Watertown MA, 02472. The company's listed phone number is (617) 923-1400 and its investor relations email address is [email protected]. The official website for Selecta Biosciences is selectabio.com. Learn More about contacing Selecta Biosciences investor relations.